clinical trial · NCT04917042

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

University of Florida →·phase2·active not recruiting·n = 10

Peripheral Nerve Sheath TumorTazemetostat

brief summary

This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.

started

Aug 25, 2021

primary completion

Feb 14, 2025

completion

Dec 1, 2026

last updated

Jun 4, 2026

official title

Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol